To help fuel its clinical trials programs on lead product candidate, cabozantinib, Exelixis Inc. (NASDAQ:EXEL) said it is planning an underwritten debt offering of $225 million convertible senior subordinated notes due 2019 and a concurrent sale of 20 million shares of its common stock

The firm will sell about 2.5 million shares of common stock and warrants to purchase 623,605 shares in units priced at $2.15 apiece...Funds will be used for general corporate purposes, which may include funding clinical trials in posterior uveitis and for other business operations

The FDA did not cite clinical safety or efficacy issues and did not request additional pre-approval studies, but the agency did raise questions relating to chemistry, manufacturing and controls, as well as issues related to a facility inspection at a third-party manufacturer. (See BioWorld Today, March 28, 2012.) The company completed an end-of-review meeting with the FDA in June to seek clarity from the agency in developing its response...FREEDOM-301 demonstrated a statistically significant

Durata Therapeutics Inc., of Morristown, N.J., said it closed its initial public offering of 8.625 million shares of common stock priced at $9 apiece, which included 1.125 million shares issued to cover overallotments, for gross proceeds of $77.6 million...Durata plans to use the proceeds to complete clinical development of lead anti-infective candidate dalbavancin, which is in a second pivotal Phase III study in acute bacterial skin and skin structure infections, and to fund commercialization

Proceeds from the financing also will support manufacturing, clinical and commercial infrastructure...Proceeds will support clinical trials of Nexagon, CoDa's lead candidate based on gap junction modulation for treating chronic wounds, including venous leg ulcers and diabetic foot ulcers...Shares of Zogenix (NASDAQ:ZGNX) closed Tuesday at $2.14, up 2 cents.

In conjunction with the facility, Alexza issued 80,429 shares of common stock to Azimuth. (See BioWorld Today, May 7, 2012...Funds also will support clinical work on a second product, a small molecule to be investigated as a possible treatment for a complication of chronic kidney disease.

Somaxon Pharmaceuticals Inc., of San Diego, said it agreed to sell about 9.4 million shares of common stock and warrants to purchase up to 4.7 million shares at a combined public offering price of 32 cents per share and per warrant, for gross proceeds of about $3 million...Upon pricing, it would trade on Nasdaq under the ticker "STML." (See BioWorld Today, April 4, 2012.)

Anthera Pharmaceuticals Inc., of Hayward, Calif., said it intends to offer and sell shares of its common stock in an underwritten public offering...and Leerink Swann LLC are acting as joint book-running managers for the offering.

It agreed to sell to investors about 19.8 million shares of common stock priced at 29 cents per share, representing gross proceeds of about $5.75 million...Net proceeds will total about $4.78 million and will be used to fund clinical trials in the U.S

Rex contributed $500,000 of the investment, and may provide its five sleep centers in Wake County as clinical trial sites for Aerial's Phase II investigational narcolepsy product...ImmunoGen Inc., of Waltham, Mass., priced a public offering of 6.25 million shares of common stock at $16 per share for gross proceeds of about $100 million to support its activities in development of cancer therapeutics, paritcularly monoclonal antibodies created with targeted antibody payload (TAP) technology

GlobeImmune is running five clinical trials, including a Phase IIb trial of GI-4000 with gemcitabine for pancreatic cancer...Palatin plans to use the proceeds for its clinical program with bremelanotide for female sexual dysfunction, preclinical and clinical development of its melanocortin receptor-1 peptide, preclinical and clinical development of PL-3994 and other corporate purposes...As part of the financing, Inter-Mountain also received warrants to purchase up to 3.1 million shares of Uluru common

Corcept plans to use the proceeds to fund R&D activities, including clinical trials...Insmed also issued Hercules a warrant to purchase 329,932 shares of common stock at $2.94 per share...Earlier this year, the FDA lifted a clinical hold on Arikace that stemmed from a long-term rat inhalation carcinogenicity study. (See BioWorld Today, Aug. 3, 2011, and May 8, 2012

Aastrom is exchanging one share of common stock for every two warrants surrendered by holders and said it already negotiated exchange agreements with holders of 7.7 million of December 2010 warrants and issued them 3.8 million shares of common stock

Each unit consisted of one share of common stock, a Class A warrant with a five-year term to purchase one-half of one share of common stock at an exercise price of $1.25 each and a Class B warrant with a 90-day term to purchase one share of common stock at an exercise price of $1 each

Under the exemption, companies may issue unregistered common stock to public investors "in exchange for one or more bona fide outstanding securities, claims or property interests," provided all the terms and conditions are approved by a court or authorized government agency...In clinical trials, 14 percent of the prior null responders with cirrhosis who received Incivek combination therapy achieved SVR vs. 10 percent in the placebo group, OPDP pointed out

As it prepares for the readouts from a handful of clinical trials in the second half of the year, rare disease developer BioMarin Pharmaceutical Inc...In the SEC filings, BioMarin reported 116.5 million shares of common stock outstanding as of May 28

Oncomed had about 126.5 million shares of common stock outstanding on March 31...served as underwriters.

The company will issue 5.8 million shares of common stock and warrants to purchase 2.9 million shares of common stock...In addition to advancing the firm's clinical and lab-based stem cell research, the investment will help support the national expansion of its Regenexx Physician Network

Fourteen clinical trials support Supernus' application for SPN-538...Nine clinical trials support Supernus' application for SPN-804...LLC to sell its common stock with a value up to $40 million